Search PubMed⌕ Search

Biomedical subjects

A Rojas

Publications and source records attributed to A Rojas.

At least 145 records · Page 8Linked to original sources

Mouse bone marrow cytogenetic damage produced by residues of tequila.

Five concentrations (50-860 mg/kg) of residues obtained after distillation and lyophilization of commercial tequila were injected into mice for evaluation of chromosome aberrations, sister-chromatid exchanges, and proliferation kinetics in mouse bone marrow cells. Appropriate positive and negative controls were included. Our results showed significant dose-related increases of chromosomal aberrations starting at 50 mg/kg and for sister-chromatid exchanges at 430 mg/kg. Cellular proliferation kinetics showed no alterations. With these data we demonstrated that the residues of tequila are genotoxic in vivo.

Alcoholic Beverages↗

Effect of normobaric oxygen on tumor radiosensitivity: fractionated studies.

The sensitizing ability of 100% normobaric oxygen was investigated in a mouse mammary carcinoma (CaNT) using a variety of fractionated regimens. Both regrowth delay and local control were used as assays of tumor response. With both assays, there was a similar and significant increase in radiosensitivity for all fractionated schedules. Enhancement ratios ranged from 1.24 to 1.45, the highest increase being observed with a 30 fraction schedule given in an overall time of 6 weeks. Thus, in CaNT tumors normobaric oxygen is a far more efficient radiosensitizer in fractionated treatments than the oxygen-mimetic compound misonidazole; an oxygen effect being observed at doses per fraction as low as 1.8 Gy. These results suggest strongly that normobaric gases could play an important role in the clinical management of tumors where hypoxia may limit the outcome of radiotherapy.

Adenocarcinoma↗

The influence of experimental design and data analysis on the determination of recovery kinetics of radiation damage between acute dose-rate treatments in vivo.

Current interest in determining the rate of recovery of damage between radiation doses in fractionated treatments has resulted in the development of several experimental designs and methods of analysis to address this. One approach is where two or more fractions are given with a varying interval. Isoeffect doses are then determined from the dose-response curves for each interval, and these are plotted on a logarithmic axis against time on a linear scale. An estimate of the rate of dose recovery can then be made if the data show monoexponential or well-defined multiexponential kinetics. However, three problems can be identified in this simple protocol. First, most repair models (e.g. Thames' IR and Curtis' LPL) assume that between two doses loge (cell survival), i.e. underlying effect, not dose itself, recovers exponentially with time. Experimental data support this assumption. Since underlying effect and dose are not linearly related, recovery measured from the change in isoeffect dose can appear substantially slower (depending on dose per fraction) than the true underlying recovery rate of damage. This artifact is avoided by converting dose increments into changes in underlying effect (with the linear-quadratic model) or by measuring underlying effect more directly in 'top-up' experiments. The use of (neutron) top-up experiments is preferred, as it enables recovery between constant X-ray doses per fraction to be studied, and makes no prior assumptions regarding either the shape of the X-ray dose-response curve or how recovery takes place, although the shape of the neutron dose-response curve must be known. Second, plotting log (unrecovered damage) against time can overestimate recovery half-times, because such plots cannot handle negative values and therefore become naturally weighted in favour of the data from the longer time intervals where the difference from complete recovery is smallest. This problem is managed by using nonlinear regression to fit the values of unrecovered damage expressed on a linear scale against interval. Third, experiments using three or more evenly spaced fractions, 'concertina'-style, permit interaction between non-adjacent fractions. If this is not taken account of, then recovery appears to be initially faster and multiexponential, even though the underlying recovery may be actually monoexponential. Thus concertina experiments are poor at resolving the precise shape of recovery-kinetics profiles and are less suited for measuring any dependence of recovery rate on dose per fraction compared with approaches using either just two fractions, or two fractions per day.

DNA Repair↗

The influence of a seventy-two hour gap on the acute response of mouse skin and oesophagus.

The sparing effect of a 72 h gap, inserted after the third, sixth or ninth fraction of a 12 fraction X-ray schedule, was investigated in two early responding normal tissues: mouse skin and oesophagus. Acute skin reactions and body weight loss were used as assays to quantify changes in the radiation tolerance of these tissues. In skin, no evidence of compensatory proliferation was seen if a gap was inserted, whatever its position in the schedule. In oesophagus, a small but significant increase in radioresistance was observed if the gap was positioned 1/4 of the way through treatment compared with the schedule delivered without an interruption (12F/12 days). Although an increase in normal tissue tolerance is not observed by increasing the overall time from 12 to 15 days, provided tumour clonogen proliferation does not occur during the weekend split, the insertion of a gap makes continuous accelerated clinical regimes, currently given without an interruption at weekends, easier to introduce into wider clinical practice.

Animals↗

Recovery kinetics in mouse skin and CaNT tumours.

Recovery kinetics and recovery capacity were studied in a fast proliferating normal tissue, skin, and in an anaplastic mouse mammary carcinoma, CaNT. Three fractions per day of X-rays, repeated over 5 days, were given at varying interfraction intervals from 0 to 8 h. The rate of recovery in tumours (t1/2 = 0.31 +/- 0.15 h for local control) was significantly faster than in skin (t1/2 = 0.96 +/- 0.10 h). By contrast, the fractionation sensitivity of CaNT tumours was less than that of skin (alpha/beta = 43.3 +/- 8.5 Gy vs. alpha/beta = 7.9 +/- 0.2 Gy). Tissues with recovery half-times similar to or longer than that determined for skin would be at risk if interfraction intervals less than 6 h are used in regimes which involve the use of two or more fractions per day. This would be especially true for tissues that show a greater sensitivity to dose fractionation, and hence more sparing of radiation damage with hyperfractionation.

Adenocarcinoma↗

The influence of dose per fraction on repair kinetics.

The use of multiple fractions per day (MFD) in radiotherapy requires information about the rate of repair of radiation injury. It is important to know the minimum interval between fractions necessary for maximum sparing of normal tissue damage, whether rate of repair is dependent on the size of dose per fraction and if it is different in early and late responding tissues and in tumours. To address these questions, the rate of repair between radiation dose fractions was measured in mouse skin (acute damage), mouse kidney (late damage) and a mouse tumour (carcinoma NT). Skin and kidney measurements were made using multiple split doses of X-rays, followed by a neutron top-up. For skin, faster recovery was obtained with 4.4 Gy fractions (t1/2 = 1.29 +/- 0.35 h, 95% CL) than with 10.5 Gy fractions (t1/2 = 3.46 +/- 0.88 h). In contrast, kidney showed slower recovery at a low dose per fraction of 2 Gy (t1/2 = 1.69 +/- 0.39 h) than at a higher dose of 7 Gy per fraction (t1/2 = 0.92 +/- 0.1 h). These data show that repair rate is dependent on the size of dose per fraction, but not in a simple way. T1/2 values now available for many different tissues generally lie in the range of 1-2 h, and are not correlated with proliferation status or early versus late response to treatment. At the doses used currently in clinical MFD treatments, these data indicate that damage in almost all normal tissues would increase if interfraction intervals less than 6 h were used.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenocarcinoma↗

Normobaric oxygen as a sensitizer of hypoxic tumor cells.

A series of experiments have been performed to determine the relative radiosensitivities of a mouse mammary tumor (CA NT) irradiated in 100% normobaric oxygen or in air, using clinically relevant dose-fractionation schedules. The results demonstrate that normobaric oxygen is a potent radiosensitizer, its effect being more marked with smaller size fractions. Enhancement ratios (ER) of 1.23 to 1.45 were obtained. By contrast, no significant benefit was seen with single doses (ER = 1.05 +/- 0.14). The degree of radiosensitization with oxygen, in these fractionated regimens, is greater than that reported for the chemical radiosensitizer, misonidazole. It therefore seems appropriate to re-examine the clinical potential of normobaric oxygen and to consider how the conditions of normobaric radiotherapy achieved in the laboratory can be translated to man.

Adenocarcinoma↗

Does the repair capacity of skin change with repeated exposure to X-rays?

A sensitive experimental design and data analysis were used to test rigorously whether the repair capacity in the skin of the mouse foot changes during a course of repeated 240 kVp X-ray doses. Any such changes might reflect saturation or induction of repair enzymes resulting from progressive radiation damage, but most importantly this assumption of equal effect per dose fraction is central to all analyses of multiple-fraction radiation treatments, and remained to be demonstrated conclusively in skin. An X-ray dose of 2.5 Gy was given two, eight, 14 or 20 times with an interfraction interval of 8 h. Individual skin reactions for each mouse were analysed separately, giving 139 estimates of the effectiveness of 2.5 Gy (approximately 35 in each of the four fractionation schedules). Regression analysis of effect per fraction versus number of fractions showed that there was no significant trend, i.e. the damage per fraction was constant regardless of the number of fractions used. The mean damage per fraction was 3.75 +/- 0.15 per cent (95 per cent CL) of the full underlying damage equivalent to transient moist desquamation, and the slope of this plot was 0.0075 per cent +/- 0.022 per cent (95 per cent CL) per fraction. It was concluded that the assumption of equal effect per fraction was not invalidated in mouse skin. Shorter interfraction intervals would not allow full repair between fractions, and this could be misinterpreted as a progressive loss of repair capacity in this type of experiment. This was tested in skin by giving 2.5 Gy doses two, eight and 14 times with a 1-h interfraction interval. Effect per fraction increased with number of fractions, by an extra 37 per cent from two to eight fractions and by a further 14 per cent from eight to 14 fractions, giving the illusion of loss of repair as predicted. This confirms the need to check that where loss of repair capacity is suspected, this is not due artifactually to incomplete repair between fractions in slowly repairing systems.

Animals↗

[Adrenal hyperplasia of late onset: optimization of therapy by measuring the circadian variation of serum 17-OH-progesterone].

A 19 yr-old female patient with the diagnosis of late onset adrenal hyperplasia was treated since age 15 with different glucocorticoid preparations and dosage schedules plus spironolactone. In spite of a very good response in terms of amelioration of their hirsutism she experienced cushingoid manifestations associated with adrenal suppression. To overcome these side effects the patient was placed on hydrocortisone 20 mg at 8 AM plus spironalactone 50 mg q.i.d. Cushingoid features vanished and response to cosyntropin (ACTH 250 ug i.m.) was reestablished. To better ascertain the effects of this treatment we studied the circadian variation in serum 17-OH progesterone after hydrocortisone was administered at 8 AM and compared it with circadian variations under basal conditions or after late-evening (11 PM) administration of hydrocortisone, 20 mg. The early morning administration of hydrocortisone was unable to prevent the nocturnal elevation of 17-OH-progesterone in spite of normal levels from 9.30 AM to 3 AM. This nocturnal peak was associated with a slightly blunted nocturnal elevation of serum cortisol. In contrast, the late evening administration of hydrocortisone was able to suppress 17-OH-progesterone to within normal levels during all day. Serum cortisol during late evening therapy was not different from that observed during early morning administration (12.2 +/- 13.1 vs 9.9 +/- 11.3 micrograms/dl, p = 0.53), yet the corresponding 17-OH-progesterone levels were much lower (0.8 +/- 0.6 vs 5.9 +/- 6.9 ng/ml). We conclude that individualization of therapy is essential in patients with late-onset adrenal hyperplasia.(ABSTRACT TRUNCATED AT 250 WORDS)

17-alpha-Hydroxyprogesterone↗

Tracheal sleeve pneumonectomy for bronchogenic carcinoma: report of 55 cases.

From 1966 to 1986, a total of 55 patients underwent a tracheal sleeve pneumonectomy (53 right and 2 left) for bronchogenic carcinoma. Preoperative radiotherapy was given in only 5 patients. The overall operative death rate was 10.9%, but no patient has died since 1975 (32 survivors). Seven patients had a postoperative empyema (12.7%); 4 of these patients had a bronchopleural fistula. Twenty-five patients had postoperative radiotherapy, 5 of whom also had chemotherapy. The actuarial survival rate, after exclusion of the 6 operative deaths, was 38% at 3 years and 23% at 5 years. Survival was correlated to regional lymph node involvement. The actuarial survival rate among patients with tumoral spread to bronchial lymph nodes was 43% at 3 years. Among the 13 patients with only subcarinal involvement, the actuarial survival rate was 34% at 3 years. None of the 8 patients with paratracheal lymph node involvement survived more than 30 months. These results indicate that tracheal sleeve pneumonectomy for bronchogenic carcinoma with extension to the carina is now fully justified considering the low operative mortality and the good results observed when lateral tracheal lymph nodes were not involved.

Adult↗

Effect of anemia on tumor radiosensitivity under normo and hyperbaric conditions.

The effect of chronic anemia on tumor radiosensitivity in a murine tumor has been investigated. Anemia was induced by bilateral kidney irradiation given several months before tumor implantation. Anemic, anemic transfused, and normal non-anemic age-matched tumor bearing animals were irradiated with X rays (2 F/24 hr) either in air, air plus misonidazole, or under hyperbaric oxygen. The most resistant response was that of tumors grown in normal mice treated in air. Anemia produced an increase in radiosensitivity which was further enhanced by red blood cell replacement. The most sensitive overall response was seen in the anemic-transfused group treated with HBO.

Adenocarcinoma↗

Replacement of the superior vena cava with polytetrafluoroethylene grafts combined with resection of mediastinal-pulmonary malignant tumors. Report of thirteen cases.

From 1979 to 1986, we replaced the superior vena cava with polytetrafluoroethylene grafts in 13 patients to enable resection of malignant mediastinal or pulmonary tumors. Five prostheses could be interposed between a tumor-free proximal superior vena cava and right atrium while eight required separate innominate anastomoses (Y grafts constructed intraoperatively). There were no deaths. Phlebograms obtained 15 to 30 days after the operation demonstrated patency in 12 of 13 patients. Long-term (average 24 months) patency was evident in eight. Five patients are alive at 1, 3, 40, 49, and 60 months, a cumulative survival rate of 27% at 3 years.

Adult↗

Fractionation studies with WR-2721: normal tissues and tumour.

We have studied the ability of WR-2721 to protect skin, kidney and an anaplastic murine tumour against single or fractionated X-ray treatments. Skin reactions, four different kidney assays, regrowth delay and local control of tumours have been used to construct dose-response curves from which the degree of radioprotection can be quantified as a protection factor. Low doses of WR-2721 (0.2-0.3 mg X g-1) were used before each of 1, 5 or 10 fractions. The degree of protection was similar in all three systems and it did not change significantly with fractionation.

Amifostine↗